Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07383701 · ClinicalTrials.gov registry record · Phase 2
Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema
A Phase 2 study, sponsored by Massachusetts Eye and Ear Infirmary.
- Not yet
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT07383701: Clinical Trial Phase 2 study, sponsored by Massachusetts Eye and Ear Infirmary.
NCT07383701 is a Phase 2 study that has not yet begun recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 36 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07383701, a Phase 2 study, has not yet begun recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This pilot prospective, interventional, longitudinal study, aims to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum 299v in patients with diabetic macular edema (DME). The study seeks to address the following questions: 1. Does central macular thickness on optical coherence tomography decrease after 4 months of supplementation? 2. Is visual acuity improved at 1, 2, 3, and 4 months following initiation of supplementation? 3. Is the number of anti-VEGF injections reduced following initiation of supplementation? Outcomes will be compared to a control group, using historic retrospective data. Participants will take Lactobacillus plantarum 299v orally twice daily for four months.
Primary Outcome
Central macular thickness (CMT) on optical coherence tomography
Interventions
- DRUG Lactobacillus plantarum 299v
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2027-09-01 |
| Phase | Phase 2 |
What is known before NCT07383701 opens enrollment
NCT07383701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% lower).
The record links to 0 conditions, and to 1 intervention - of which Lactobacillus plantarum 299v is the first listed.
NCT07383701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07383701 about?
NCT07383701 is a clinical study titled "Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema". This pilot prospective, interventional, longitudinal study, aims to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum 299v in patients with diabetic macular edema (DME). The study seeks to address the following questions: 1. Does central macular thickness on optic...
What is the current status of trial NCT07383701?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-08-01. Estimated completion is 2027-09-01.
What interventions are being tested in trial NCT07383701?
The interventions under investigation include: Lactobacillus plantarum 299v (DRUG).
Who is sponsoring clinical trial NCT07383701?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07383701's enrollment target sits among peer trials
36 1496th of 2000 higher than 477 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI